Related Experiment Video
Updated: Jan 18, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative
Peng Xian1, Linghui Zou1, Jiaxin Zhang1
1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Abstract:
Cancer-associated fibroblasts (CAFs), major components of the triple-negative breast cancer (TNBC) tumor microenvironment, affect tumor growth and limit the therapeutic efficacy of various clinical approaches by forming a dense stromal physical barrier, inducing chemo-resistance and promoting a tumor-immunosuppressive microenvironment. Therefore, therapeutic strategies based on targeted modulation of CAFs are promising in the treatment of TNBC. However, precise targeting of CAFs faces difficulties due to the lack of specific markers for CAFs. Here, we designed a nanoparticle co-modified with anisamide and CAF cell membrane (CAFm) to load tetrandrine as a CAF nano-regulator (TET@ACNP), which is able to precisely target and modulate CAFs. Precise targeting of CAFs was achieved by the combination of the CAFm homing effect as well as the high affinity effect between anisamide and sigma receptors overexpressed on CAFs. TET@ACNP was able to inhibit CAFs activation and reduce collagen secretion, thereby breaking the physical barrier to facilitate the penetration of the first-line chemotherapeutic agent docetaxel (DTX) and the infiltration of cytotoxic T lymphocytes. In addition, TET@ACNP alleviates chemoresistance by inhibiting the Wnt/β-catenin pathway and inhibits IGF2 expression to release the immunosuppressive microenvironment, ultimately enhancing chemotherapy effects and anti-tumor immunity. Our study proposes a comprehensive therapeutic strategy based on the precise targeting and regulation of CAFs in combination with chemotherapy to achieve multifaceted inhibition of TNBC. This is expected to be a universal platform to improve the therapeutic efficacy of different chemotherapeutic agents in various types of stroma-rich tumors.
Insights
Targeting cancer-associated fibroblasts (CAFs) with novel nanoparticles (TET@ACNP) effectively inhibits triple-negative breast cancer (TNBC) growth. This strategy enhances chemotherapy and boosts anti-tumor immunity by modulating the tumor microenvironment.
Area of Science:
- Oncology
- Nanomedicine
- Cancer Biology
Background:
- Cancer-associated fibroblasts (CAFs) are key components of the triple-negative breast cancer (TNBC) tumor microenvironment.
- CAFs contribute to tumor growth, chemoresistance, and immunosuppression by forming a dense stromal barrier.
- Targeting CAFs presents a promising therapeutic strategy for TNBC, but lacks specific markers for precise targeting.
Purpose of the Study:
- To design a nanoparticle-based drug delivery system for precise targeting and modulation of CAFs in TNBC.
- To evaluate the efficacy of the designed nanoparticle in inhibiting CAF activation, overcoming chemoresistance, and enhancing anti-tumor immunity.
Main Methods:
- Development of a nanoparticle (TET@ACNP) co-modified with anisamide and CAF cell membrane (CAFm) to load tetrandrine.
- Utilizing CAFm homing and anisamide-sigma receptor interaction for precise CAF targeting.
- Assessing the impact of TET@ACNP on CAF activation, collagen secretion, drug penetration, immune cell infiltration, Wnt/β-catenin pathway, and IGF2 expression.
Main Results:
- TET@ACNP precisely targeted and modulated CAFs, inhibiting their activation and reducing collagen secretion.
- The nanoparticle broke down the stromal barrier, facilitating docetaxel (DTX) penetration and cytotoxic T lymphocyte infiltration.
- TET@ACNP alleviated chemoresistance by inhibiting the Wnt/β-catenin pathway and suppressed IGF2, thereby releasing the immunosuppressive microenvironment.
Conclusions:
- Precise targeting and regulation of CAFs using TET@ACNP offer a multifaceted approach to inhibit TNBC.
- This strategy enhances chemotherapy efficacy and boosts anti-tumor immunity.
- The developed platform holds potential for improving therapeutic outcomes in various stroma-rich tumors.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

